Dominican RepublicTuberculosis profile
Population  2014 10 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.41 (0.22–0.65) 3.9 (2.2–6.2)
Mortality (HIV+TB only) 0.19 (0.15–0.24) 1.8 (1.4–2.3)
Prevalence  (includes HIV+TB) 7.6 (4–12) 73 (39–117)
Incidence  (includes HIV+TB) 6.2 (5.5–7) 60 (53–68)
Incidence (HIV+TB only) 1.7 (1.4–1.9) 16 (14–19)
         
Case detection, all forms (%) 71 (63–80)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 11 (6.1–17)
MDR-TB cases among notified pulmonary
TB cases
89 (43–140) 64 (34–94)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 630   300
Pulmonary, clinically diagnosed 926   64
Extrapulmonary 483   2
       
Total new and relapse 4 405    
Previously treated, excluding relapses 200    
Total cases notified 4 605    
Among 4 405 new and relapse cases:
47 (1%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 240 (9%) 176 (31%) 470
Laboratory-confirmed RR-/MDR-TB cases     93
Patients started on MDR-TB treatment ***     127
TB/HIV 2014 Number (%)
TB patients with known HIV status 3 377 (73)
HIV-positive TB patients 782 (23)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 370 (47)
HIV-positive TB patients on antiretroviral therapy (ART) 667 (85)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 945  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (83) 2 898
Previously treated cases, excluding relapse, registered in 2013 (51) 162
HIV-positive TB cases, all types, registered in 2013 (65) 263
RR-/MDR-TB cases started on second-line treatment in 2012 (72) 100
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 6.2
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 21
% Funded domestically 64%
% Funded internationally 14%
% Unfunded 22%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-03 Data: www.who.int/tb/data